RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M

RenovoRx, Inc.

Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.
FY2026 revenue guidance raised to $3.75-4.25M from $3-4M, implying ~241-286% YoY growth.
21 active commercial cancer centers (+30% from 16 in Q1); 63 in pipeline; Q3 revenue expected to exceed Q2.
Phase III TIGeR-PaC fully enrolled; 78/86 events; completion H1 2027, topline H2 2027.
First RenovoCath use in sarcoma patient; cash $9.5M, sufficient into H2 2027; break-even target Q4 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.